Treatment of Community-Acquired Moraxella catarrhalis Pneumonia in Healthy Adult Outpatients Without Comorbidities
Clinical Scenario
An adult outpatient presents with community-acquired pneumonia. They have no significant chronic comorbidities and no identified risk factors for infection with antibiotic-resistant pathogens, making them candidates for an outpatient oral treatment strategy.
Patient Population
This protocol applies when the patient meets all of the following criteria:
- No chronic heart, lung, liver, or renal disease; no diabetes mellitus; no alcoholism; no malignancy; no asplenia.
- No prior respiratory isolation of MRSA or Pseudomonas aeruginosa.
- No recent hospitalisation with receipt of parenteral antibiotics within the past 90 days.
Recommended Approach
Empiric oral monotherapy is the recommended strategy for this patient group. Agent selection is guided by local resistance patterns.
The full structured protocol — including specific antibiotic options, dosing, and duration guidance — is available via the link below.
Treatment Goals
The clinical endpoint is stability: resolution of vital sign abnormalities (heart rate, respiratory rate, blood pressure, oxygen saturation, and temperature), ability to eat, and normal mentation. Most patients reach this endpoint within 48 to 72 hours of starting treatment.
References
DOI: 10.1164/rccm.201908-1581ST
- For healthy outpatient adults without comorbidities listed below or risk factors for antibiotic resistant pathogens, we recommend (Table 3):
- Comorbidities include chronic heart, lung, liver, or renal disease; diabetes mellitus; alcoholism; malignancy; or asplenia.
- Risk factors include prior respiratory isolation of MRSA or P. aeruginosa or recent hospitalization AND receipt of parenteral antibiotics (in the last 90 d).
- As recent data supporting antibiotic administration for <5 days are scant, on a risk–benefit basis we recommend treating for a minimum of 5 days, even if the patient has reached clinical stability before 5 days.
- A variety of criteria for determining clinical improvement have been developed for patients with CAP and validated in clinical trials, including resolution of vital sign abnormalities (heart rate, respiratory rate, blood pressure, oxygen saturation, and temperature), ability to eat, and normal mentation.
- As most patients will achieve clinical stability within the first 48 to 72 hours, a total duration of therapy of 5 days will be appropriate for most patients.
View source ↗